Anna Vossenkaemper

Title: Dr
Dr med
Lecturer in Mucosal Immunology

Anna Vossenkaemper’s research focuses on the mucosal immune system in the gut in healthy individuals and patients with inflammatory bowel disease. In her current project, collaboration with GlaxoSmithKline, she concentrates on intestinal inflammatory disorders and the inhibition of RIP1 and RIP2 kinases as a potential new way of treating these conditions. Anna works in close collaboration with Prof Jo Spencer (characterization of human Peyer's patch B cells) and Dr Andrew Stagg (phenotyping of Peyer's patch dendritic cells). Anna also reviews various journals, incl. 'Clinical & Experimental Immunology', the 'PLOS' journals and 'Annals of Tropical Medicine & Parasitology'. Her work is currently funded by GlaxoSmithKline.  


Anna Vossenkaemper studied medicine from 1998-2004 at the Free University Berlin (Germany), Saint Radboud University Nijmegen (the Netherlands) and the Catholic University Leuven (Belgium). She graduated in 2004 with an MD in immunology, obtained for work on interleukin-18 in the acute murine ileitis following Toxoplasma gondii infection (lab of Prof Oliver Liesenfeld, Charité Berlin).

She joined the Anchored Signaling Group of Dr Enno Klussmann (Leibniz-Institute of Molecular Pharmacology, Berlin, Germany) in 2005 and did research on cAMP-regulation of arginine-vasopressin-mediated water reabsorption and intracellular transport mechanisms of the renal water channel aquaporin-2.

In 2006 she joined the group of Prof Thomas MacDonald at Barts and the London where she started her research on human gut-associated lymphoid tissue and intestinal dendritic cells. Her current research concentrates on intestinal inflammatory disorders and new ways of treating these conditions. She further focuses on the phenotyping and better understanding of B cells in human Peyer's patches. Anna holds an Advanced Diploma in Nutrition from the Royal Society for Public Health.


Gut-associated lymphoid tissue in health and disease;

New treatment strategies for inflammatory bowel disease


A role for gut-associated lymphoid tissue in shaping the human B cell repertoire.  A.Vossenkämper, P. Blair, N. Safinia, L.D. Fraser, L. Das, T. J. Sanders,  A. J. Stagg, J. D. Sanderson, K. Taylor, F. Chang, LM Choong, D. P. D’Cruz, T. T. MacDonald, G. Lombardi and J. Spencer. J Exp Med 2013 210: 1665-1674.

Immunoglobulin A-producing plasma cells originate from germinal centers that are induced by B-cell receptor engagement in humans. Francesca Barone*, Anna Vossenkämper*, Laurent Boursier, Wen Su, Alan Watson, Susan John, Deborah Dunn-Walters, Paul Fields, Jonathan Edgeworth, and Jo Spencer. Gastroenterology 2010; 140(3):947-56. * joined first author.

Inhibition of NFkappaB signaling in human dendritic cells by the enteropathogenic Escherichia coli effector protein NleE. Anna Vossenkämper , Olivier Marchès, Gary Warnes, Peter D. Fairclough, James O. Lindsay, Andrew J. Stagg , Paul C. Evans, Le A. Luong, Nicholas M. Croft, Sandhia Naik, Gad Frankel, and Thomas T. MacDonald. J Immunol. 2010 Sep 10.

Both IL-12 and IL-18 contribute to small intestinal Th1-type immunopathology following oral infection with Toxoplasma gondii, but IL-12 is dominant over IL-18 in parasite control. Vossenkämper A, Struck D, Alvarado-Esquivel C, Went T, Takeda K, Akira S, Pfeffer K, Alber G, Lochner M, Forster I, Liesenfeld O. Eur. J. Immunol. 2004. 34: No.11, 3197-3207

View all Anna Vossenkaemper's Research Publications at:


Centre for Immunology and Infectious Disease
 Blizard Institute
Barts and The London School of Medicine and Dentistry
Blizard Building
4 Newark Street
E1 2AT

020 7882 2311
This email address is being protected from spambots. You need JavaScript enabled to view it.